Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1974 Oct;180(4):635–641. doi: 10.1097/00000658-197410000-00029

BCG Immunotherapy of Malignant Melanoma: Summary of a Seven-year Experience

Donald L Morton, Frederick R Eilber, E Carmack Holmes, John S Hunt, Alfred S Ketcham, Melvin J Silverstein, Frank C Sparks
PMCID: PMC1344159  PMID: 4412271

Abstract

Over the past 7 years, 151 patients with malignant melanoma have been treated with BCG immunotherapy alone or as an adjunct to surgical therapy. Direct injection of metastatic melanoma lesions limited to skin resulted in 90% regression of injected lesions and 17% regression of uninjected lesions in immunocompetent patients. Approximately 25% of these patients remained free of disease for 1 to 6 years. Direct injections of BCG into nodules of patients with subcutaneous or visceral metastases resulted in a lower incidence of local control and no long term survivors. Attempts to improve the results of immunotherapy in these patients by palliative surgical resection of large metastatic lesions to lower tumor burden followed by BCG immunotherapy significantly improved the results although many patients still developed recurrent disease. Early results of a clinical trial combining BCG immunotherapy with regional lymphadenectomy in patients with melanoma metastatic to lymph nodes have been encouraging and promising. Further controlled clinical trials are necessary to elucidate the role of BCG in immunotherapy. However, since BCG is but one of a number of potential immunologic adjuvants, even more effective immunotherapy will be possible as further knowledge of the interactions of cellular and humoral immunity is acquired.

Full text

PDF
635

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CUTLER S. J., EDERER F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 1958 Dec;8(6):699–712. doi: 10.1016/0021-9681(58)90126-7. [DOI] [PubMed] [Google Scholar]
  2. Eilber F. R., Morton D. L. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970 Feb;25(2):362–367. doi: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  3. Gutterman J. U., Mavligit G., McBride C., Frei E., 3rd, Freireich E. J., Hersh E. M. Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet. 1973 Jun 2;1(7814):1208–1212. doi: 10.1016/s0140-6736(73)90526-6. [DOI] [PubMed] [Google Scholar]
  4. Hellström I., Hellström K. E., Sjögren H. O., Warner G. A. Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int J Cancer. 1971 Jan 15;7(1):1–16. doi: 10.1002/ijc.2910070102. [DOI] [PubMed] [Google Scholar]
  5. Lewis M. G., Ikonopisov R. L., Nairn R. C., Phillips T. M., Fairley G. H., Bodenham D. C., Alexander P. Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J. 1969 Sep 6;3(5670):547–552. doi: 10.1136/bmj.3.5670.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Morton D. L., Eilber F. R., Joseph W. L., Wood W. C., Trahan E., Ketcham A. S. Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann Surg. 1970 Oct;172(4):740–749. doi: 10.1097/00000658-197010000-00018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Morton D. L., Malmgren R. A., Holmes E. C., Ketcham A. S. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery. 1968 Jul;64(1):233–240. [PubMed] [Google Scholar]
  8. Morton D., Eilber F. R., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970 Jul;68(1):158–164. [PubMed] [Google Scholar]
  9. Muna N. M., Marcus S., Smart C. Detection by immunofluorescence of antibodies specific for human malignant melanoma cells. Cancer. 1969 Jan;23(1):88–93. doi: 10.1002/1097-0142(196901)23:1<88::aid-cncr2820230109>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  10. Oettgen H. F., Aoki T., Old L. J., Boyse E. A., de Harven E., Mills G. M. Suspension culture of a pigment-producing cell line derived from a human malignant melanoma. J Natl Cancer Inst. 1968 Oct;41(4):827–843. [PubMed] [Google Scholar]
  11. Seigler H. F., Shingleton W. W., Metzgar R. S., Buckley C. E., Bergoc P. M., Miller D. S., Fetter B. F., Phaup M. B. Non-specific and specific immunotherapy in patients with melanoma. Surgery. 1972 Jul;72(1):162–174. [PubMed] [Google Scholar]
  12. Sparks F. C., Silverstein M. J., Hunt J. S., Haskell C. M., Pilch Y. H., Morton D. L. Complications of BCG immunotherapy in patients with cancer. N Engl J Med. 1973 Oct 18;289(16):827–830. doi: 10.1056/NEJM197310182891603. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES